Literature DB >> 1549899

The significance of inflammation and regression in melanoma.

M G Cook.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1549899     DOI： 10.1007/bf02358800

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN： 0174-7398


× No keyword cloud information.
  23 in total

1.  Characterization of proliferative cells in malignant melanomas and their inflammatory infiltrates.

Authors:  J Simony; J F Rossi; B Shishehian; E Ursule; M Radal; H Pujol
Journal:  Cancer Detect Prev       Date:  1991

2.  Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma.

Authors:  F J Tefany; R S Barnetson; G M Halliday; S W McCarthy; W H McCarthy
Journal:  J Invest Dermatol       Date:  1991-08       Impact factor: 8.551

3.  Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases.

Authors:  H M Shaw; S W McCarthy; W H McCarthy; J F Thompson; G W Milton
Journal:  Histopathology       Date:  1989-09       Impact factor: 5.087

4.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

5.  Metastases of thin melanomas.

Authors:  H Trau; D S Rigel; M N Harris; A W Kopf; R J Friedman; S L Gumport; R S Bart; W R Grier
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

6.  Biologic behavior of thin malignant melanomas with regressive changes.

Authors:  R R Paladugu; R H Yonemoto
Journal:  Arch Surg       Date:  1983-01

7.  Plasma cells within the infiltrate of primary cutaneous malignant melanoma of the skin. A confirmation of its histoprognostic value.

Authors:  J M Mascaro; M Molgo; T Castel; J Castro
Journal:  Am J Dermatopathol       Date:  1987-12       Impact factor: 1.533

8.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

9.  Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.

Authors:  M J Kornstein; J S Brooks; D E Elder
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance.

Authors:  P H Cooper; H J Wanebo; R W Hagar
Journal:  Arch Dermatol       Date:  1985-09
View more
  6 in total

1.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

2.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

3.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

4.  High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.

Authors:  Sook Jung Yun; Phyllis A Gimotty; Wei-Ting Hwang; Peter Dawson; Patricia Van Belle; David E Elder; Rosalie Elenitsas; Lynn Schuchter; Paul J Zhang; DuPont Guerry; Xiaowei Xu
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

5.  Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology.

Authors:  Anna Batistatou; Martin G Cook; Daniela Massi
Journal:  Virchows Arch       Date:  2009-04-08       Impact factor: 4.064

6.  Evolving pharmacotherapies for the treatment of metastatic melanoma.

Authors:  April K S Salama
Journal:  Clin Med Insights Oncol       Date:  2013-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.